Most cases were reported as serious (62.3%), citing ‘other medically important condition’ as the primary reason for seriousness (58.6%), and 68.8% of all cases involved cannabis extracts. Causality was assessed for 668 events; most were assessed as being ‘possibly’ associated with the reported cannabis product.
GLP-1 Receptor Agonist Side Effects: New Clinical Evidence
GLP-1 Clinical Relevance #42Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic GLP-1 Side EffectsPatient Reported OutcomesReal World EvidenceForum Data AnalysisWegovy Mounjaro Safety Why This Matters Family...